Vanta Bioscience Ltd
BSE:540729
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (85.4), the stock would be worth ₹-162.39 (1 099% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -8.5 | ₹16.25 |
0%
|
| Industry Average | 85.4 | ₹-162.39 |
-1 099%
|
| Country Average | 35.9 | ₹-68.28 |
-520%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Vanta Bioscience Ltd
BSE:540729
|
115.6m INR | -8.5 | -2.6 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 1 841 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
173.3B USD | 31.1 | 25.3 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.5B USD | 26.2 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 105.4 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
331.7B CNY | 24.7 | 16.8 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.5B CHF | -164.9 | -119.4 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.5B USD | 33.3 | 24.4 | |
| US |
|
Waters Corp
NYSE:WAT
|
28.7B USD | 53.8 | 44.6 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.6B USD | 18.7 | 19.6 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.2B USD | 32.1 | 29 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 20.7 |
| Median | 35.9 |
| 70th Percentile | 64.8 |
| Max | 50 585.9 |
Other Multiples
Vanta Bioscience Ltd
Glance View
Vanta Bioscience Ltd. engages in the full service preclinical contract research organization. The company is headquartered in Secunderabad, Telangana. The company went IPO on 2017-10-06. The firm is engaged in research and development in the field of discovery and development of drugs, biological, vaccines, gene-based therapies, as well as diagnostics and cosmetics, including clinical research. The company provides risk assessment services for evaluating the safety of the active pharmaceutical ingredients (API), excipients, extractable and leachable, including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. The company also provides expert services for determination of health-based exposure limits, such as permitted daily exposure (PDE) or allowable daily exposure (ADE), including occupational exposure limits (OEL) for pharmaceutical manufacturers. The firm's subsidiaries include Vanta Clinical Research Limited and Vayam Research Solutions Limited.
